Lebedeva Natalya Valerievna

Lebedeva Natalya Valerievna

Biography

2022: Appointment to the position of general director of Angiolaine

In June 2022, it became known about the appointment of Natalia Lebedeva as the new general director of Angiolain. The change of chapter came amid a corporate conflict within the manufacturer of medical devices for interventional cardiac surgery.

Earlier, the founders of Angiolain, Andrei Kudryashov and Alexei Frantsev, were expelled from the shareholders by decision of the Arbitration Court of the Novosibirsk Region. In total, entrepreneurs owned almost three quarters of the company's shares (37.2% each).

During the proceedings, the court considered that Kudryashov and the French caused significant harm to the company during the corporate conflict in 2017-2022. As RBC wrote, Lebedeva stated that she was removed from decision-making, and the actions of other shareholders had the goal of reducing her share in JSC (25%). She received shares in return for investments in 2013.

In mid-May 2022, the Supreme Court of the Russian Federation refused to Andrei Kudryashov and Alexei Frantsuzov to transfer to the Judicial Board for Economic Disputes a cassation appeal against the decision of lower instances that declared illegal the withdrawal of the main asset - the production company Angiolain Intervenshional Devices - from JSC to legal entities controlled by Kudryashov and Frantsuzov (Latrek LLC, Hart Invest LLC and Evron LLC). According to the judges of the RF Armed Forces, the deal bore the signs of a "pretend" and pursued the ultimate goal of withdrawing assets during a corporate conflict with another shareholder of the company, Natalya Lebedeva.

In June 2022, it became known that Angiolaine had stopped the production of medical devices for cardiac surgery. According to Natalia Lebedeva (BFM- contacted her), as Novosibirsk general director of the company, she will restart the enterprise "in the near future."^[1]

2024: Detention in Moscow

In June 2024, Natalya Lebedeva, co-owner of Angiolain, a company specializing in the production of medical devices for cardiology, was detained in Moscow. She was detained as part of the investigation of a criminal case on large-scale embezzlement, initiated under Article 160 of the Criminal Code of the Russian Federation. The maximum punishment under this article provides for up to ten years in prison.

According to TASS, Natalya Lebedeva will be transferred from Moscow to Novosibirsk, where the Sovetsky District Court will consider the issue of choosing a preventive measure for her. Lebedeva is one of the key figures in the corporate conflict within the company, which has been going on for several years.

source = Angiolaine

According to the agency, Natalya Lebedeva has been a participant in the corporate conflict within Angiolain for several years. In April 2024, the company's shareholder Maxim Zolotukhin and the company itself appealed to the Arbitration Court of the Novosibirsk Region with a demand to recognize Lebedeva's ownership of Angiolain shares as invalid. The court granted the application and seized the disputed shares, banning Lebedeva from making transactions with them.

According to sources in law enforcement agencies, Lebedeva is accused of embezzlement or embezzlement of someone else's property on an especially large scale. The move is a continuation of a corporate conflict that began back in 2017, when Lebedeva challenged the additional issue of the company's shares, arguing that the decision was made without a quorum of shareholders. Then the court sided with Lebedeva.

According to TASS, the Angiolain company is known for its achievements in the field of cardiology. In 2019, she launched a production complex at the Biotechnopark site worth 500 million rubles. The company's products, including stents and catheters, are used in the diagnosis and treatment of heart and vascular diseases.^[2]

Notes